|
HTC
|
|
|
Juventas Therapeutics, headquartered in the Cleveland Health-Tech Corridor, is a privately-held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life-threatening diseases.
Founded in 2007 with exclusively licensed intellectual property developed at the Cleveland Clinic, Juventas has secured more than $10 million in venture capital and grant funding to transition its therapeutic platform from concept to initiation of mid-stage clinical trials. Investors include Triathlon Medical Venture Partners, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, North Coast Angel Fund, X Gen Ltd., Jumpstart Inc., and Blue Chip Venture Co.
Juventas Therapeutics has received non-dilutive grant support through the Ohio Third Frontier funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.
The company’s lead product, JVS-100 encodes Stromal-Cell Derived Factor 1 (SDF-1) which has been shown to promote tissue repair through activation of natural stem-cell repair pathways, promotion of new blood vessel formation and prevention of ongoing cell death.
Juventas has been developing JVS-100 for use as a platform technology for cardiovascular and wound healing applications. It received FDA authorization for Phase II clinical trials to test the product on patients with critical limb ischemia, a severe blockage of the arteries that reduces blood flow to the extremities. There are approximately 3 million U.S. citizens with this condition, with hospital treatment costs for these patients exceeding $10 billion.
Juventas has spun off a new company, SironRX, to develop the application of JVS-100 to help wounds heal and prevent scarring in post-surgical wounds.
|
|
|
|
|
|